FY2026 Earnings Forecast for Evolus Issued By HC Wainwright

Evolus, Inc. (NASDAQ:EOLS) – Investment analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Evolus in a research note issued to investors on Thursday, April 10th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $0.41 per share for the year, down from their prior forecast of $0.49. HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.20 EPS and FY2029 earnings at $3.60 EPS.

A number of other equities research analysts have also commented on the stock. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday. Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th.

Evolus Trading Up 1.4 %

NASDAQ:EOLS opened at $9.54 on Friday. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market capitalization of $606.62 million, a PE ratio of -10.48 and a beta of 0.97. The business’s 50-day simple moving average is $12.91 and its 200-day simple moving average is $13.33. Evolus has a fifty-two week low of $8.67 and a fifty-two week high of $17.82.

Insiders Place Their Bets

In related news, CFO Sandra Beaver sold 8,996 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the completion of the sale, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. The trade was a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rui Avelar sold 27,904 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the sale, the insider now owns 362,467 shares of the company’s stock, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 60,575 shares of company stock valued at $794,369 over the last ninety days. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolus

Several hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its position in shares of Evolus by 4.1% during the 1st quarter. Rhumbline Advisers now owns 83,436 shares of the company’s stock worth $1,004,000 after buying an additional 3,287 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Evolus by 1,765.9% in the 1st quarter. GAMMA Investing LLC now owns 18,622 shares of the company’s stock worth $224,000 after purchasing an additional 17,624 shares during the period. Jefferies Financial Group Inc. bought a new stake in Evolus during the fourth quarter valued at $753,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Evolus by 6.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company’s stock valued at $1,270,000 after purchasing an additional 6,821 shares in the last quarter. Finally, Zimmer Partners LP boosted its holdings in shares of Evolus by 66.6% during the 4th quarter. Zimmer Partners LP now owns 416,500 shares of the company’s stock worth $4,598,000 after buying an additional 166,500 shares in the last quarter. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.